



Synlogic to Host Analyst & Investor Event at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

November 1, 2018

- Presentations to feature key opinion leaders and expand on preclinical data from Synlogic's first immuno-oncology candidate, accepted for presentation at SITC 2018 -

- Company to webcast event, beginning at 12:30 p.m. ET on Saturday, November 10, 2018 -

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 1, 2018-- Synlogic, Inc. ([Nasdaq: SYBX](#)), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced that the Company will host an event for analysts and investors in conjunction with the Society for Immunotherapy of Cancer's 33rd Annual Meeting * Pre-Conference Programs (SITC 2018), with formal presentations beginning at 12:30 pm ET on November 10, 2018.

At SITC 2018, Synlogic will deliver a poster presentation of preclinical data for its innate immune activator candidate. Details about the poster presentation and abstract are below:

- **Title:** Development of a STING Agonist-producing Synthetic Biotic™ Medicine to Activate Innate and Adaptive Immunity and Drive Antitumor Immune Responses
- **Abstract ID:** P624
- **Location:** Poster Hall Location: Hall E
- **Time:** Friday, Nov. 9 from 8:00 am– 8:00 pm ET and Saturday, Nov. 10 from 8:00 am – 8:30 pm ET

The analyst and investor event will expand on these data to highlight the potential of Synlogic's Synthetic Biotic platform in immuno-oncology, with featured speakers including:

- Synlogic management
- Filip Janku, MD, PhD; MD Anderson Cancer Center
- Dmitriy Zamarin, MD, PhD; Memorial Sloan Kettering Cancer Center

A live webcast of the presentation and accompanying slides will be available under "[Events and Presentations](#)" in the News & Investors section of the Company's website at www.synlogictx.com. An archived webcast recording of the event will be available on the website for approximately 30 days.

About Synlogic

Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The company's two lead programs, SYN1020 and SYN1618, target hyperammonemia as a result of liver damage or genetic disease, and PKU, respectively. When delivered orally, Synthetic Biotic medicines can act from the gut to compensate for the dysfunctional metabolic pathway and have a systemic effect, with the potential to significantly improve symptoms of disease for affected patients. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's platform to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism, liver disease, inflammatory and immune disorders, and cancer; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; the potential of Synlogic's technology to treat hyperammonemia and phenylketonuria; and the expected timing of Synlogic's anticipated clinical trial initiations. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181101006038/en/>

Source: Synlogic, Inc.

MEDIA CONTACT:

Synlogic

Courtney Heath, 617-872-2462

courtney@scientpr.com

or

INVESTOR CONTACT:

Synlogic

Elizabeth Wolffe, Ph.D., 617-207-5509

liz@synlogictx.com